• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EXOSC5：肺腺癌预后不良的一种新型生物标志物。

EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.

作者信息

Xu Jianxun, Zhang Zhengwei, Han Keyao, Yang Zhen, Guo Fengmei

机构信息

Affiliated Hospital of Nantong University, Nantong, China.

出版信息

BMC Cancer. 2025 Apr 14;25(1):681. doi: 10.1186/s12885-025-14059-2.

DOI:10.1186/s12885-025-14059-2
PMID:40229765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11995474/
Abstract

BACKGROUND

Exosome complex gene 5 (EXOSC5), a member of the exosome complex family, is highly tumorigenic in various cancers. However, its prognostic value and underlying mechanisms in lung adenocarcinoma (LUAD) remain unclear.

METHODS

We analysed LUAD data from The Cancer Genome Atlas (TCGA) via bioinformatics tools. Logistic regression was used to assess the associations between clinical information and EXOSC5 expression in LUAD patients. EXOSC5 expression was validated by immunohistochemistry (IHC) and western blotting, and its functional role was investigated through gene set enrichment analysis (GSEA) and in vitro experiments.

RESULTS

EXOSC5 was significantly upregulated in LUAD and associated with poor prognosis. The risk model based on EXOSC5 expression outperformed the traditional staging system for prognosis prediction. EXOSC5 promoted tumor progression by regulating the cell cycle, proliferation, and immune cell infiltration. High EXOSC5 expression was correlated with resistance to anti-PD1 immunotherapy.

CONCLUSION

EXOSC5 is a novel oncogenic factor in LUAD that promotes tumor progression and immune evasion and may serve as a prognostic biomarker and therapeutic target.

摘要

背景

外切体复合物基因5（EXOSC5）是外切体复合物家族的成员，在多种癌症中具有高度致瘤性。然而，其在肺腺癌（LUAD）中的预后价值及潜在机制仍不清楚。

方法

我们通过生物信息学工具分析了来自癌症基因组图谱（TCGA）的LUAD数据。采用逻辑回归评估LUAD患者临床信息与EXOSC5表达之间的关联。通过免疫组织化学（IHC）和蛋白质印迹法验证EXOSC5表达，并通过基因集富集分析（GSEA）和体外实验研究其功能作用。

结果

EXOSC5在LUAD中显著上调，并与预后不良相关。基于EXOSC5表达的风险模型在预后预测方面优于传统分期系统。EXOSC5通过调节细胞周期、增殖和免疫细胞浸润促进肿瘤进展。EXOSC5高表达与抗PD1免疫治疗耐药相关。

结论

EXOSC5是LUAD中一种新型致癌因子，可促进肿瘤进展和免疫逃逸，可能作为一种预后生物标志物和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/83fcf61f229c/12885_2025_14059_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/d28cc22dc212/12885_2025_14059_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/f1d24cba4d1a/12885_2025_14059_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/c5d1d40dfba4/12885_2025_14059_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/918f6b30bc0b/12885_2025_14059_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/d5c7870b9286/12885_2025_14059_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/2e724674e5e0/12885_2025_14059_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/83fcf61f229c/12885_2025_14059_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/d28cc22dc212/12885_2025_14059_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/f1d24cba4d1a/12885_2025_14059_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/c5d1d40dfba4/12885_2025_14059_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/918f6b30bc0b/12885_2025_14059_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/d5c7870b9286/12885_2025_14059_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/2e724674e5e0/12885_2025_14059_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1631/11995474/83fcf61f229c/12885_2025_14059_Fig7_HTML.jpg

相似文献

1
EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.EXOSC5：肺腺癌预后不良的一种新型生物标志物。
BMC Cancer. 2025 Apr 14;25(1):681. doi: 10.1186/s12885-025-14059-2.
2
Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.SEC61G 在肺腺癌中的预后价值：基于生物信息学和体外验证的综合研究。
BMC Cancer. 2021 Nov 13;21(1):1216. doi: 10.1186/s12885-021-08957-4.
3
The role of EMG1 in lung adenocarcinoma progression: Implications for prognosis and immune cell infiltration.EMG1 在肺腺癌进展中的作用：对预后和免疫细胞浸润的影响。
Int Immunopharmacol. 2024 Sep 10;138:112553. doi: 10.1016/j.intimp.2024.112553. Epub 2024 Jun 28.
4
Estrogen sulfotransferase SULT1E1 expression correlates with progression and prognosis of lung adenocarcinoma.雌激素硫酸转移酶SULT1E1的表达与肺腺癌的进展和预后相关。
Sci Rep. 2025 Jan 6;15(1):925. doi: 10.1038/s41598-024-82129-9.
5
Comprehensive analysis identifies YKT6 as a potential prognostic and diagnostic biomarker in lung adenocarcinoma.综合分析鉴定 YKT6 为肺腺癌潜在的预后和诊断生物标志物。
BMC Cancer. 2024 Oct 7;24(1):1235. doi: 10.1186/s12885-024-12975-3.
6
FAM207A acts as a novel and potential biomarker in lung adenocarcinoma and shapes the immunesuppressive tumor microenvironment.FAM207A作为肺腺癌中一种新型的潜在生物标志物，并塑造免疫抑制性肿瘤微环境。
Clin Exp Med. 2025 Apr 21;25(1):125. doi: 10.1007/s10238-025-01657-4.
7
High TLX1 Expression Correlates with Poor Prognosis and Immune Infiltrates in Patients with Lung Adenocarcinoma.TLX1 高表达与肺腺癌患者的不良预后和免疫浸润相关。
Curr Mol Med. 2024;24(6):801-812. doi: 10.2174/1566524023666230619123752.
8
NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.NGEF 是一种潜在的预后生物标志物，可作为肺腺癌免疫治疗和化疗的指标。
BMC Pulm Med. 2024 May 19;24(1):248. doi: 10.1186/s12890-024-03046-1.
9
DCUN1D5 is a prognostic biomarker and correlated immune infiltrates and glycolysis in lung adenocarcinoma.DCUN1D5是一种预后生物标志物，与肺腺癌中的免疫浸润和糖酵解相关。
Sci Rep. 2025 Jan 2;15(1):403. doi: 10.1038/s41598-024-84539-1.
10
Unveiling the Enigmatic Role of SLC35F3 in Lung Adenocarcinoma.揭示 SLC35F3 在肺腺癌中的神秘作用。
Clin Respir J. 2024 Oct;18(10):e70023. doi: 10.1111/crj.70023.

本文引用的文献

1
M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma.M2 巨噬细胞分泌的外泌体促进肝癌转移并增加血管通透性。
Cell Commun Signal. 2023 Oct 30;21(1):299. doi: 10.1186/s12964-022-00872-w.
2
Cancer epigenetics in clinical practice.癌症表观遗传学在临床实践中的应用。
CA Cancer J Clin. 2023 Jul-Aug;73(4):376-424. doi: 10.3322/caac.21765. Epub 2022 Dec 13.
3
Mitochondrial DNA variation and cancer.线粒体 DNA 变异与癌症。
Nat Rev Cancer. 2021 Jul;21(7):431-445. doi: 10.1038/s41568-021-00358-w. Epub 2021 May 27.
4
The influences of TGF-β1 upon the human adenocarcinoma cell of lung A549 and cellular immunity.转化生长因子-β1对人肺腺癌细胞A549及细胞免疫的影响。
Ann Transl Med. 2020 Sep;8(17):1076. doi: 10.21037/atm-20-4437.
5
EXOSC9 depletion attenuates P-body formation, stress resistance, and tumorigenicity of cancer cells.EXOSC9 缺失可减弱液泡形成、增强癌细胞应激抗性和致瘤性。
Sci Rep. 2020 Jun 9;10(1):9275. doi: 10.1038/s41598-020-66455-2.
6
N6‑methyladenosine RNA methylation regulators participate in malignant progression and have prognostic value in clear cell renal cell carcinoma.N6-甲基腺苷 RNA 甲基化调控因子参与肾透明细胞癌的恶性进展，并具有预后价值。
Oncol Rep. 2020 May;43(5):1591-1605. doi: 10.3892/or.2020.7524. Epub 2020 Feb 28.
7
EXOSC5 as a Novel Prognostic Marker Promotes Proliferation of Colorectal Cancer via Activating the ERK and AKT Pathways.EXOSC5作为一种新型预后标志物，通过激活ERK和AKT通路促进结直肠癌增殖。
Front Oncol. 2019 Jul 18;9:643. doi: 10.3389/fonc.2019.00643. eCollection 2019.
8
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
9
Induction of antiinflammatory purinergic signaling in activated human iNKT cells.活化的人 iNKT 细胞中抗炎嘌呤能信号的诱导。
JCI Insight. 2018 Sep 6;3(17). doi: 10.1172/jci.insight.91954.
10
4L Lymph Node Involvement in Left-Sided Lung Cancer: Unique or Not?左侧肺癌中4L淋巴结受累：是否独特？
J Clin Oncol. 2018 Oct 10;36(29):2907-2908. doi: 10.1200/JCO.2018.79.3299. Epub 2018 Aug 27.